BioCentury | Oct 14, 2013
Company News

Competitive Technologies management update

Competitive Technologies Inc. (OTCQX:CTTC), Fairfield, Conn. Business: Neurology, Supply/Service Hired: Conrad Mir as president, CEO, interim CFO and a director, formerly CFO of Pressure BioSciences Inc. ; he succeeds Carl O'Connell, who remains a director...
BioCentury | Jan 28, 2008
Company News

Competitive Technologies Inc., Palatin deal

...MT-II to Competitive Technologies. Palatin retains rights to PT-141 bremelanotide, an active metabolite of MT-II that Competitive Technologies...
...license in a 2005 lawsuit. In 2005, the companies settled a separate dispute in which Competitive Technologies...
...treat erectile dysfunction (ED) and is in Phase I testing to treat female sexual dysfunction. Competitive Technologies...
BioCentury | Jan 2, 2006
Company News

Competitive Technologies Inc., Genzyme deal

...payment and is eligible for royalties. Homocysteine is a marker for cardiovascular and neurodegenerative diseases. Competitive Technologies...
BioCentury | Sep 5, 2005
Company News

Competitive Technologies Inc., Dade Behring deal

...tests for cardiovascular diseases. CTT will receive a license fee and is eligible for royalties. Competitive Technologies...
BioCentury | Aug 8, 2005
Company News

Competitive Technologies Inc., J&J deal

...counterparts covering homocysteine tests. CTT will receive a license fee and is eligible for royalties. Competitive Technologies...
BioCentury | Aug 8, 2005
Company News

Competitive Technologies Inc., EpiTan, Melanotan Corp. deal

...cells in vertebrates. Melanotan has sub-licensed CTT's portfolio to EPT. CTT is eligible for royalties. Competitive Technologies...
BioCentury | Aug 1, 2005
Company News

Competitive Technologies, Beckman Coulter deal

...counterparts covering homocysteine tests. CTT will receive a license fee and is eligible for royalties. Competitive Technologies...
BioCentury | Jun 27, 2005
Company News

Palatin, Competitive Technologies Inc. genitourinary news

...KG, Bristol, Tenn.) and is in Phase II testing. Palatin Technologies Inc. (PTN), Princeton, N.J. Competitive Technologies...
BioCentury | May 2, 2005
Company News

Axis-Shield, Competitive Technologies Inc. diagnostic news

...will receive a license fee and is eligible for royalties. Axis-Shield plc (LSE:ASD), Dundee, U.K. Competitive Technologies...
BioCentury | Dec 20, 2004
Company News

Competitive Technologies Inc., Abbott deal

...to CTT. ABT will pay royalties on sales of tests that use the CTT technology. Competitive Technologies...
Items per page:
1 - 10 of 24
BioCentury | Oct 14, 2013
Company News

Competitive Technologies management update

Competitive Technologies Inc. (OTCQX:CTTC), Fairfield, Conn. Business: Neurology, Supply/Service Hired: Conrad Mir as president, CEO, interim CFO and a director, formerly CFO of Pressure BioSciences Inc. ; he succeeds Carl O'Connell, who remains a director...
BioCentury | Jan 28, 2008
Company News

Competitive Technologies Inc., Palatin deal

...MT-II to Competitive Technologies. Palatin retains rights to PT-141 bremelanotide, an active metabolite of MT-II that Competitive Technologies...
...license in a 2005 lawsuit. In 2005, the companies settled a separate dispute in which Competitive Technologies...
...treat erectile dysfunction (ED) and is in Phase I testing to treat female sexual dysfunction. Competitive Technologies...
BioCentury | Jan 2, 2006
Company News

Competitive Technologies Inc., Genzyme deal

...payment and is eligible for royalties. Homocysteine is a marker for cardiovascular and neurodegenerative diseases. Competitive Technologies...
BioCentury | Sep 5, 2005
Company News

Competitive Technologies Inc., Dade Behring deal

...tests for cardiovascular diseases. CTT will receive a license fee and is eligible for royalties. Competitive Technologies...
BioCentury | Aug 8, 2005
Company News

Competitive Technologies Inc., J&J deal

...counterparts covering homocysteine tests. CTT will receive a license fee and is eligible for royalties. Competitive Technologies...
BioCentury | Aug 8, 2005
Company News

Competitive Technologies Inc., EpiTan, Melanotan Corp. deal

...cells in vertebrates. Melanotan has sub-licensed CTT's portfolio to EPT. CTT is eligible for royalties. Competitive Technologies...
BioCentury | Aug 1, 2005
Company News

Competitive Technologies, Beckman Coulter deal

...counterparts covering homocysteine tests. CTT will receive a license fee and is eligible for royalties. Competitive Technologies...
BioCentury | Jun 27, 2005
Company News

Palatin, Competitive Technologies Inc. genitourinary news

...KG, Bristol, Tenn.) and is in Phase II testing. Palatin Technologies Inc. (PTN), Princeton, N.J. Competitive Technologies...
BioCentury | May 2, 2005
Company News

Axis-Shield, Competitive Technologies Inc. diagnostic news

...will receive a license fee and is eligible for royalties. Axis-Shield plc (LSE:ASD), Dundee, U.K. Competitive Technologies...
BioCentury | Dec 20, 2004
Company News

Competitive Technologies Inc., Abbott deal

...to CTT. ABT will pay royalties on sales of tests that use the CTT technology. Competitive Technologies...
Items per page:
1 - 10 of 24